Cargando…

Biosimilar Drugs: What Would Be a Reasonable Extrapolation?

Detalles Bibliográficos
Autores principales:	Gifoni, Markus A.C., Fernandes, Gustavo S., Chammas, Roger
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Clinical Oncology 2017
Materias:	Commentaries
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180803/ https://www.ncbi.nlm.nih.gov/pubmed/30241152 http://dx.doi.org/10.1200/JGO.2016.008342

Ejemplares similares

The use of biosimilar medicines in oncology - position statement of the Brazilian Society of Clinical Oncology (SBOC)
por: Fernandes, G.S., et al.
Publicado: (2018)

Biosimilars and the extrapolation of indications for inflammatory conditions
por: Tesser, John RP, et al.
Publicado: (2017)

Biosimilars: Extrapolating the evidence. A roundtable discussion
por: Monk, Bradley J., et al.
Publicado: (2015)

When is it reasonable to extrapolate during a pandemic?: The case of broad UK labeling for AstraZeneca COVID-19 vaccine
por: Dal-Ré, Rafael, et al.
Publicado: (2021)

Controversies in Establishing Biosimilarity: Extrapolation of Indications and Global Labeling Practices
por: Ebbers, Hans C., et al.
Publicado: (2016)

Extrapolation concept at work with biosimilar: a decade of experience in oncology
por: Krendyukov, Andriy, et al.
Publicado: (2018)

Extrapolation in Practice: Lessons from 10 Years with Biosimilar Filgrastim
por: Gascon, Pere, et al.
Publicado: (2019)

Biosimilar Drugs for Multiple Sclerosis: An Unmet International Need or a Regulatory Risk?
por: Rivera, Victor M.
Publicado: (2019)

Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
por: Mysler, Eduardo, et al.
Publicado: (2021)

Confusion about Cadmium Risks: The Unrecognized Limitations of an Extrapolated Paradigm
por: Bernard, Alfred
Publicado: (2015)

What are Altmetrics and why would anyone be interested?
por: Watson, Roger
Publicado: (2016)

Biosimilar and interchangeable: Inseparable scientific concepts?
por: de Mora, Fernando, et al.
Publicado: (2019)

Interchangeability of Biosimilars: Overcoming the Final Hurdles
por: Barbier, Liese, et al.
Publicado: (2021)

Commentary: Biosimilars in the treatment of retinopathy of prematurity
por: Soni, Tanvi, et al.
Publicado: (2023)

Barriers to Oncology Biosimilars Uptake in the United States
por: Nabhan, Chadi, et al.
Publicado: (2018)

Biosimilars: a regulatory perspective from America
por: Kay, Jonathan
Publicado: (2011)

Practical Issues Concerning the Approval and Use of Biosimilar Drugs for the Treatment of Multiple Sclerosis in Latin America
por: Steinberg, Judith, et al.
Publicado: (2019)

If these myocytes could talk, they would speak the language of metabolites
por: Bailey, Logan R.J., et al.
Publicado: (2022)

Would you like to be contacted about future research?
por: Newington, Lisa, et al.
Publicado: (2021)

An extrapolation of Foucault’s Technologies of the Self to effect positive transformation in the intensivist as teacher and mentor
por: Papadimos, Thomas J, et al.
Publicado: (2013)

Adequacy of safety data for regulatory approval of pediatric indication through extrapolation algorithm
por: Park, Min Soo
Publicado: (2021)

Biomedical and Market Issues Surrounding the Advent of Biosimilars
por: Cline, Abigail, et al.
Publicado: (2016)

Would ivermectin for malaria control be beneficial in onchocerciasis-endemic regions?
por: Siewe Fodjo, Joseph Nelson, et al.
Publicado: (2019)

Biosimilars for Rheumatoid Arthritis: Riding the 2023 Wave [Podcast]
por: Cohen, Stanley B, et al.
Publicado: (2023)

Expanding Footprints of Biosimilar Tenecteplase
por: Subhash, et al.
Publicado: (2023)

What Eugenics Would Accomplish
Publicado: (1912)

What Would Become of Nuclear Risk if Governments Changed Their Regulations to Recognize the Evidence of Radiation’s Beneficial Health Effects for Exposures That Are Below the Thresholds for Detrimental Effects?
por: Cuttler, Jerry M., et al.
Publicado: (2021)

Polio: abandoning eradication would result in rapid resurgence of an ancient scourge
por: Sutter, Roland Walter, et al.
Publicado: (2019)

To See or NOsee: The Debate on the Nocebo Effect and Optimizing the Use of Biosimilars
por: Rezk, Mourad F., et al.
Publicado: (2018)

EU pharmacovigilance regulatory requirements of anticancer biosimilar monoclonal antibodies
por: Francescon, Sara, et al.
Publicado: (2018)

Commentary: Use of biosimilars for retinal diseases in India: Challenges and concerns
por: Kumar, Aman, et al.
Publicado: (2021)

Why would a black man volunteer for a government-funded science experiment?
por: Nduom, Edjah K.
Publicado: (2021)

Why would associations between cardiometabolic risk factors and depressive symptoms be linear?
por: de Jonge, Peter, et al.
Publicado: (2014)

Would offering vegetables to children for breakfast increase their total daily vegetable intake?
por: McLeod, Chris J, et al.
Publicado: (2022)

Could, would, should: Theory of mind and deontic reasoning in Tongan children
por: Taumoepeau, Mele, et al.
Publicado: (2022)

The road to biosimilars in rare diseases ‐ ongoing lessons from Gaucher disease
por: Drelichman, Guillermo, et al.
Publicado: (2019)

Assessing Clinical Equivalence in Oncology Biosimilar Trials With Time-to-Event Outcomes
por: Uno, Hajime, et al.
Publicado: (2019)

Metrics and evaluation of scientific productivity: would it be useful to normalize the data taking in consideration the investments?
por: de Marco, Ario
Publicado: (2019)

Would program performance indicators and a nationally coordinated response accelerate the elimination of tuberculosis in Canada?
por: Heffernan, Courtney, et al.
Publicado: (2018)

Plant hormone transporters: what we know and what we would like to know
por: Park, Jiyoung, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_dfn1ivvgok57raijsrtas9kir7